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Source of ﬁnancjournal homepage: www.elsevier .com/ locate / jva lLETTERS TO THE EDITORCost-Effectiveness of Expanded Newborn Screening in TexasWe read with great interest the study by Tiwana et al. [1]
regarding a critical issue in public health: cost-effective measures
in expanded newborn screening. According to their results,
although expanded screening was associated with increased
costs, it improved quality of life. Therefore, the authors con-
cluded that expanded newborn screening, as compared with
unexpanded screening, was a cost-effective option in Texas.
Some analytic problems in this article, however, need further
clariﬁcation.
The authors likely miscalculated the incremental cost-
effectiveness ratio (ICER) in Table 6. Conventionally, the ICER is
calculated by using the following formula:
ICER ¼ (Costwith screening – Costwithout screening)/(Effectwith screening
– Effectwithout screening)ost and effectiveness by disorder at 3%
With screening
Cost ($) Effectiveness
81,455.00 14.34 5
67,699.00 24.09 3
36,607.00 25.03
66,711.00 24.56 2
91,269.00 24.73 2
84,436.00 23.46 1
acidemia; CIT, citrullinemia; COAD, classical organic
st-effectiveness ratio; MCADD, medium chain acyl-Co
year.
ial support: The authors have no other ﬁnancial rWhile in Table 6, the ICER was miscalculated as
ICER ¼ [(Costwith screening – Cost without screening)/Effectwith screening]
– Effectwithout screening
The corrected Table 6 content is listed below. Based on our
corrections, the ICER should be $47,079 per quality-adjusted life-
year (QALY) for arginosuccinic acidemia and citrullinemia, $5,254
per QALY for maple syrup urine disease, $3,397 per QALY for
medium chain acyl-CoA dehydrogenase deﬁciency (MCADD),
$15,378 per QALY for glutaric acidemia type I, and $4,973 per QALY
for classical organic acid disorders. Therefore, it would be better that
the relevant parts in the main text, including the ﬁrst paragraph of
the Results (p. 616) and the second paragraph in the Discussion
(p. 618), are carefully reexamined and properly readdressed.Without screening ICER ($/QALY)
Cost ($) Effectiveness
38,334.00 11.3 9,969.24
33,594.00 21.04 Dominant
36,303.00 5.94 4,001.41
50,678.00 19.84 632.97
17,145.00 19.91 2,977.42
42,468.00 15.02 1,773.90
acid disorders; GA-1, glutaric acidemia type I; HCY, homocystinuria;
A dehydrogenase deﬁciency; MSUD, maple syrup urine disease; QALY,
elationships to disclose.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 0 3 – 1 1 0 41104CorrectedTable 6 – Average cost and effectiveness by disorder at 3%
Disorder With screening Without screening ICER ($/QALY)
Cost ($) Effectiveness Cost ($) Effectiveness
ASA_CIT 681,455.00 14.34 538,334.00 11.3 47,079.28
HCY 267,699.00 24.09 333,594.00 21.04 Dominant
MSUD 136,607.00 25.03 36,303.00 5.94 5,254.27
MCADD 266,711.00 24.56 250,678.00 19.84 3,396.82
GA-I 291,269.00 24.73 217,145.00 19.91 15,378.42
COAD 184,436.00 23.46 142,468.00 15.02 4,972.51
ASA, arginosuccinic acidemia; CIT, citrullinemia; COAD, classical organic acid disorders; GA-1, glutaric acidemia type I; HCY, homocystinuria;
ICER, incremental cost-effectiveness ratio; MCADD, medium chain acyl-CoA dehydrogenase deﬁciency; MSUD, maple syrup urine disease; QALY,
quality-adjusted life-year.The corrected ICER is more consistent with that in previous
studies. Insinga et al. [2] reported an estimate of $41,862 per QALY
for MCADD inWisconsin. Prosser et al.’s [3] study disclosed that the
cost-effectiveness of newborn screening for MCADD was $27,423
per QALY. In Canada, Cipriano et al. [4], who assessed the cost-
effectiveness of expanding newborn screening for six diseases,
showed that the ICER was $1,440,777 per life-year (LY) gained for
arginosuccinic acidemia, $1,753,719 per LY gained for citrullinemia,
$331,200 per LY gained for homocystinuria, $15,426 per LY gained
for maple syrup urine disease, $62,798 per LY gained for MCADD,
and $48,071 per LY gained for glutaric acidemia type I [4].
Although the threshold of cost-effectiveness for medical inter-
ventions is roughly £20,000 to 30,000 in the United Kingdom,
and US $50,000 to $100,000 in the United States, it is well accepted
that these values are unjustiﬁed [5]. The use of $50,000 as a limit to
determine cost-effectiveness was set in the early 1980s, and was
used widely after 1996 [6]. Many recent studies have challenged
these values by using willingness to pay [5–7]. For example,
the willingness-to-pay values in Shiroiwa et al.’s [5] study
were £23,000 in the United Kingdom and US $62,000 in the United
States.
Despite the unjustiﬁed cost-effectiveness limit, the ICER of
expanded newborn screening in this study, $11,560 per QALY, is
still far below the limit. The conclusion that expanded newborn
screening is a cost-effective strategy, despite the errata men-
tioned above, remains robust and convincible.
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